RxDoctor Payments Data

Jared Newman, DO

Family Medicine · Jamesburg, NJNPI 1093806010

Payments from drug & device makers

$704in general payments, 2019–2025

Across 19 payments — averaging $37.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$196
  • Zimmer Biomet$169
  • Novo Nordisk$140
  • Johnson & Johnson$116
  • GSK$32
  • Boehringer Ingelheim$19
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$704 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$279,685
Medicare patients
631
Services billed
3,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide34$62,648
EliquisApixaban92$44,673
OzempicSemaglutide24$44,537
JanuviaSitagliptin Phosphate50$44,013
XareltoRivaroxaban111$36,950
MounjaroTirzepatide20$31,093
JardianceEmpagliflozin23$28,676
FarxigaDapagliflozin Propanediol24$26,987
ProliaDenosumab12$20,450
MyrbetriqMirabegron30$10,702
Rosuvastatin Calcium280$4,950
Atorvastatin Calcium366$4,349
Midodrine Hcl44$4,125
ArexvyRsvpref3 Antigen/As01e/Pf13$4,088
Levothyroxine Sodium313$3,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$140$107,18558 claims
Johnson & JohnsonXarelto$116$36,950111 claims
Lilly USA, LLCMounjaro$16$31,09320 claims
Boehringer IngelheimJardiance$19$28,67623 claims
AstraZenecaFarxiga$17$26,98724 claims
GSKArexvy$32$4,08813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Jamesburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →